Ischemic stroke therapy

Annual Review of Medicine

Volumn 53, Issue , 2002, Pages 453-475

  Stapf, C ^a   Mohr, J P ^a  

^a NEUROLOGICAL INSTITUTE   (United States)

Author keywords

Cerebral infarction; Hospitalization; Stroke management

Indexed keywords

ACETYLSALICYLIC ACID; ALTEPLASE; ANCROD; ANTIHYPERTENSIVE AGENT; ANTIPYRETIC ANALGESIC AGENT; BARBITURIC ACID DERIVATIVE; CARBAMAZEPINE; CLONIDINE; CLOPIDOGREL; DIAZEPAM; DIPYRIDAMOLE; GLUCOSE; GLYCEROL; GLYCERYL TRINITRATE; HEPARIN; HEPARINOID; INSULIN; LABETALOL; LORAZEPAM; LOW MOLECULAR WEIGHT HEPARIN; MANNITOL; NADROPARIN; NITROPRUSSIDE SODIUM; PHENYTOIN; THIOPENTAL; TROMETAMOL; URAPIDIL;

ALGORITHM; BLEEDING; BLOOD CLOT LYSIS; BRAIN INFARCTION; CAROTID ENDARTERECTOMY; CEREBROVASCULAR ACCIDENT; CLINICAL FEATURE; CLINICAL TRIAL; DECOMPRESSION SURGERY; DEEP VEIN THROMBOSIS; DIAGNOSTIC PROCEDURE; DIFFERENTIAL DIAGNOSIS; DISEASE CLASSIFICATION; DRUG INDICATION; FEVER; HEART ARRHYTHMIA; HOSPITALIZATION; HUMAN; HYPERTENSION; HYPOTENSION; HYPOVENTILATION; INTRACRANIAL HYPERTENSION; LUNG GAS EXCHANGE; METABOLIC DISORDER; PATIENT MONITORING; PERCUTANEOUS TRANSLUMINAL ANGIOPLASTY; PRACTICE GUIDELINE; PRIMARY PREVENTION; PRIORITY JOURNAL; REVASCULARIZATION; REVIEW; RISK FACTOR; SECONDARY PREVENTION; SEIZURE; STENT; THROMBOCYTE AGGREGATION;

ACUTE DISEASE; CEREBRAL INFARCTION; DISABILITY EVALUATION; HOSPITAL UNITS; HUMANS; PROGNOSIS; SURVIVAL RATE; THROMBOLYTIC THERAPY; TISSUE PLASMINOGEN ACTIVATOR;

EID: 0036182922     PISSN: 00664219     EISSN: None     Source Type: Book Series    
DOI: 10.1146/annurev.med.53.082901.104106     Document Type: Review

References (128)

1. The greater cincinnati/Northern Kentucky stroke study: Preliminary first-ever and total incidence rates of stroke among blacks
2. The end of the long-term decline in stroke mortality in the United States?
3. Primary prevention of stroke. A statement for healthcare professionals from the Stroke Council of the American Heart Association
4. Stroke incidence, prevalence, and survival: Secular trends in Rochester, Minnesota, through 1989
5. Secular trends in stroke incidence and mortality: The Framingham study
6. Stroke incidence among white, black, and Hispanic residents of an urban community
7. Familial aggregation of stroke: The Framingham study
8. Effectiveness versus efficacy of treatment of hypertension for stroke prevention
9. Cigarette smoking as a risk factor for stroke: The Framingham study
10. Effect of intensive blood glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34)
11. Cholesterol reduction and the risk for stroke in men: A meta-analysis of randomized, controlled trials
12. Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation: Analysis of pooled data from five randomized controlled trials
13. Prevention of a first stroke by transfusion in children with sickle cell anemia and abnormal results on transcranial Doppler ultrasonography
14. Body size and fat distribution as predictors of stroke among US men
15. A prospective study of body mass index, weight change, and the risk of stroke in women
16. Leisure-time physical activity and ischemic stroke risk: The Northern Manhattan stroke study
17. The protective effect of moderate alcohol consumption on ischemic stroke
18. A quantitative assessment of plasma homocysteine as a risk factor for vascular disease: Probable benefits of increasing folic acid intakes
19. Ischemic stroke risk with oral contraceptives: A meta-analysis
20. Endarterectomy for asymptomatic carotid artery stenosis
21. Prospective study on the complication rate of carotid surgery
22. The stroke data bank: Design, methods, and baseline characteristics
23. The Lausanne stroke registry: Analysis of 1000 consecutive patients with first stroke
24. Classification and natural history of clinically indentifiable subtypes of cerebral infarction
25. Stroke incidence and survival among middle-aged adults: 9-Year follow-up of the Atherosclerosis Risk in Communities (ARIC) cohort
26. Hypertension and diabetes mellitus as determinants of multiple lacunar infarcts
27. Testing the validity of the lacunar hypothesis: The Northern Manhattan stroke study experience
28. Predictive value of lacunar syndromes for lacunar lesions on magnetic resonance brain imaging
29. The natural history of lacunar infarction: The Oxfordshire Community stroke project
30. Clinical study of 227 patients with lacunar infarcts
31. Epidemiological characteristics of lacunar infarcts in a population
32. Predictors of mortality and recurrence after hospitalized cerebral infarction in an urban community: The Northern Manhattan stroke study
33. Long-term prognosis of symptomatic lacunar infarcts. A hospital-based study
34. Long-term prognosis of first-ever lacunar strokes. A hospital-based study
35. The Lausanne stroke registry: Analysis of 1,000 consecutive patients with first stroke
36. Predisposing factors for cerebral infarction: The Oxfordshire community stroke project
37. Cardiac sources of embolism in patients with pial artery infarcts and lacunar strokes
38. Neurological complications of cardiac valvular disease and cardiac surgery including systemic hypotension
39. The pathogenesis of watershed infarcts in the brain
40. Borderzone infarctions distal to carotid artery occlusion: Prognostic implications
41. Internal borderzone infarction following acute middle cerebral artery occlusion
42. Distal field infarction
43. Man-in-the-barrel syndrome
44. An analysis of the time of presentation after stroke
45. Perceptions and knowledge of stroke among surviving patients with stroke and their carers
46. Factors delaying hospital admission after acute stroke
47. Time of hospital presentation in patients with acute stroke
48. De-mystifying recognition and management of stroke
49. Optimizing intensive care in stroke: A European perspective
50. Guidelines for the managemant of patients with acute ischemic stroke. A statement for healthcare professionals from a special writing group of the Stroke Council, American Heart Association
51. Do stroke units save lives?
52. The effect of a stroke unit: Reductions in mortality, discharge rate to nursing home, length of hospital stay, and cost. A community-based study
53. Tissue plasminogen activator for acute ischemic stroke
54. Guidelines for thrombolytic therapy for acute ischemic stroke: A supplement to the guidelines for the management of patients with acute ischemic stroke. A statement for healthcare professionals from a special writing group of the Stroke Council, American Heart Association
55. Intravenous thrombolysis with recombinant tissue plasminogen activator for acute hemispheric stroke
56. Randomized double-blind placebo-controlled trial of thrombolytic therapy with intravenous Alteplase in acute ischemic stroke (ECASS II)
57. Recombinant tissue-type plasminogen activator (Alteplase) for ischemic stroke 3 to 5 hours after symptom onset
58. Intracerebral hemorrhage after rt-PA therapy for ischemic stroke
59. Protocol violations in community-based rTPA stroke treatment are associated with symptomatic intracerebral hemorrhage
60. Cerebral hemorrhage after systemic fibrinolysis in a patient with severe carotid artery stenosis
61. Generalized efficacy of t-PA for acute stroke: Subgroup analysis of the NINDS rt-PA stroke trial
62. Intravenous ancrod for treatment of acute ischemic stroke. The STAT study: A randomized controlled trial
63. The International Stroke Trial (IST): A randomized trial of aspirine, subcutaneous heparin, both, or neither among 10435 patients with acute ischemic stroke
64. CAST: Randomized placebo-controlled trial of early aspirin use in 20000 patients with acute stroke
65. Dipyridamole and acetylsalicylic acid in the secondary prevention of stroke
66. A randomized, blinded, trial of clopidogrel versus aspirin in patients at risk for ischemic events (CAPRIE)
67. Low dose heparin as a prophylaxis against deep vein thrombosis after acute stroke
68. A double-blind randomized trial of Org 10172 low molecular weight heparinoid in prevention of deep vein thrombosis in thrombotic stroke
69. Prophylaxis of deep venous thrombosis with a low molecular weight heparin (Kabi 2165/Fragmin) in stroke patients
70. A low-molecular-weight heparinoid compared with unfractionated heparin in the prevention of deep venous thrombosis in patients with acute ischemic stroke. A randomized, double-blind study
71. Low-molecular-weight heparin for the treatment of acute ischemic stroke
72. Low molecular weight heparinoid, ORG 10172 (danaparoid), and outcome after acute ischemic stroke: A randomized controlled trial
73. Low molecular-weight heparin versus aspirin in patients with acute ischemc stroke and atrial fibrillation: A double blind randomised study
74. Immediate anticoagulation in acute focal brain ischemia revisited. Gathering the evidence
75. Carotid artery dissection
76. Guidelines for thrombolytic therapy for acute ischemic stroke: A supplement to the guidelines for the management of patients with acute ischemic stroke. A statement for healthcare professionals from a special writing group of the Stroke Council, American Heart Association
77. Late intra-arterial thrombolysis
78. PROACT: A phase II randomized trial of recombinant pro-urokinase by direct arterial delivery in acute middle cerebral artery stroke
79. Intra-arterial prourokinase for acute ischemic stroke. The PROACT II study: A randomized controlled trial
80. Carotid stenting and angioplasty. A statement for healthcare professionals from the Councils on Cardiovascular Radiology, Stroke, Cardio-Thoracic and Vascular Surgery, Epidemiology and Prevention, and Clinical Cardiology, American Heart Association
81. Carotid artery stenosis: Treatment with protected balloon angioplasty and stent placement
82. Elective stenting of the extracranial carotid arteries
83. Carotid angioplasty and stenting: Are they therapeutic alternatives?
84. CREST (Carotid Revascularization Endarterectomy versus Stent Trial): Background, design, and current status
85. Protocol for the International Carotid Stenting Study (ICSS)
86. Intracranial percutaneous transluminal angioplasty for arteriosclerotic stenosis
87. Provisional stenting for symptomatic intracranial stenosis using a multidisciplinary approach: Acute results, unexpected benefit, and one-year outcome
88. Symptomatic middle cerebral artery stenosis: Should angioplasty be attempted?
89. Safety and efficacy of percutaneous transluminal angioplasty for intracranial atherosclerotic disease
90. Transluminal angioplasty for atherosclerotic disease of vertebral and basilar arteries
91. The "malignant" middle cerebral artery infarction: Clinical course and neuroradiological signs
92. Decompressive surgery in space-occupying hemispheric infarction: Results of an open prospective trial
93. Treatment of right hemispheric cerebral infarction by hemicraniectomy
94. Hemicraniectomy in space-occupying hemispheric infarction: Useful early intervention or desperate activism?
95. Hemicraniectomy in elderly patients with space occupying media infarction: Improved survival but poor functional outcome
96. Transtentorial herniation after unilateral infarction of the anterior cerebral artery
97. Decompressive surgery in space-occupying hemispheric infarction. A randomized controlled trial
98. Intensive care in acute stroke
99. Therapeutic strategies in space-occupying cerebellar infarction based on clinical, neuroradiological, and neurophysiological data
100. Surgical treatment of cerebellar infarction
101. Beneficial effect of carotid endarterectomy in symptomatic patients with high grade carotid stenosis
102. Benefit of carotid endarterectomy in patients with symptomatic moderate or severe stenosis
103. MRC European carotid surgery trial: Iterim results for symptomatic patients with severe (70-90%) or with mild (0-29%) carotid stenosis
104. Hemorrhage complication in carotid endarterectomy
105. Early carotid endarterectomy in patients with small, fixed neurologic deficits
106. Timing of endarterectomy after acute stroke
107. Early endarterectomy for severe carotid artery stenosis after a nondisabling stroke: Results from the North American Symptomatic Carotid Endarterectomy Trial
108. Clinical features of moyamoya disease in the United States
109. Long-term results of surgically treated moyamoya disease
110. Rapid and near-complete resolution of moyamoya vessels in a patient with superficial temporal artery-to-middle cerebral artery bypass
111. Encephaloduroarteriosynangiosis (EDASS) for the treatment of childhood moyamoya disease
112. MR angiography of moyamoya disease before and after encephaloduroarteriosynangiosis
113. Body temperature in acute stroke: Relation to stroke severity, infact size, mortality, and outcome
114. Survival and recurrence following stroke: The Framingham study
115. Survival and recurrence after first cerebral infarction: A population-based study in Rochester, Minnesota, 1975 through 1989
116. Predictors of mortality and recurrence after hospitalized cerebral infarction in an urban community: The Northern Manhattan stroke study
117. Stroke recurrence within 2 years after ischemic infarction
118. Preventing ischemic stroke in patients with prior stroke and transient ischemic attack. A statement for healthcare professionals from the Stroke Council American Heart Association
119. Secondary prevention in non-rheumatic atrial fibrillation after transient ischemic attack or minor stroke
120. The Warfarin-Aspirin Recurrent Stroke Study (WARSS): Initial results